Groups want to know about patent extensions amid political scrutiny of drug prices
Shareholder proposals targeting major pharmaceutical companies and resolutions looking into corporate spending on political activities are among those featuring in what is set to be another groundbreaking US proxy season for ESG.
Ahead of this year’s AGMs, the Interfaith Center on Corporate Responsibility (ICCR) co-ordinated the filing of proposals with nine pharmaceutical companies about their use of intellectual property. The companies at issue are AbbVie, Amgen, Bristol Myers Squibb, Eli
To continue reading you need an active subscription
- Quarterly issues of IR Magazine
- Unlimited Articles online
- Newsletter
- Investor Perception Studies – Europe, US, Canada and Asia
- Strategy guides
- Whitepapers
- Benchmarking reports
From
$995*
Ben Maiden
Ben Maiden is the editor-at-large of Corporate Secretary, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
Editor-at-large, Corporate Secretary
